Status of TMPRSS2-ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism.

Bhanushali, Aparna; Rao, Pranesh; Raman, Vaishnavi; Kokate, Prajakta; Ambekar, Asawari; Mandva, Swarna; Bhatia, Simi; Das, B R

Status of TMPRSS2-ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism.

Bhanushali, Aparna; Rao, Pranesh; Raman, Vaishnavi; Kokate, Prajakta; Ambekar, Asawari; Mandva, Swarna; Bhatia, Simi; Das, B R.

Afiliação

Bhanushali A; Research and Development, SRL Ltd, Mumbai 400 062, India.
Rao P; Research and Development, SRL Ltd, Mumbai 400 062, India.
Raman V; Research and Development, SRL Ltd, Mumbai 400 062, India.
Kokate P; Department of Cytogenetics, SRL Ltd, India.
Ambekar A; Department of Histopathology, Apollo Hospital, Vashi, India.
Mandva S; Department of Cytogenetics, SRL Ltd, India.
Bhatia S; Department of Histopathology, SRL Ltd, India.
Das BR; Research and Development, SRL Ltd, Mumbai 400 062, India.

Prostate Int ; 6(4): 145-150, 2018 Dec.

Article em En | MEDLINE | ID: mdl-30505817

Palavras-chave

Fluorescence in situ hybridization; Indians; Prostate cancer; Single nucleotide polymorphism; TMPRSS2ERG; rs12329760

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article